Ex-Pfizer employee, business partner charged with insider trading on COVID drug trial results

  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 53%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

A former Pfizer employee and their close friend are facing insider trading charges after federal officials claim they traded on non-public drug trial results in 2021.

After Pfizer CEO Albert Bourla referred to the results as a "game-changer" in the global efforts to end the pandemic, the company's stock rose by nearly 11%. That marked the largest single-day price move in Pfizer's stock since 2009, according to the SEC."Insider trading is not a quick buck. It’s not easy money. It’s not a sure thing. It’s cheating. It’s a bad bet. It’s a ticket to prison," U.S. Attorney Damian Williams said in a statement Thursday.

Pfizer told FOX Business that the company is cooperating with the government's investigation into the matter. "The charges in this case relate to the personal conduct of a former Pfizer employee in violation of the company’s policies," a Pfizer spokesperson told FOX Business. At the time of the trade, Dagar was a senior statistical program lead for the Paxlovid drug trial, which began in July 2021, according to the

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 458. in JP

日本 最新ニュース, 日本 見出し